CEDARHURST, N.Y., Feb. 08, 2019 (GLOBE NEWSWIRE) -- The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are encouraged to contact the firm regarding possible appointment as lead plaintiff and a preliminary estimate of their recoverable losses.

If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the respective securities during the class periods. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No classes have yet been certified in the actions below. Appointment as lead plaintiff is not required to partake in any recovery.

Yangtze River Port and Logistics Limited (NASDAQGS: YRIV)
Investors Affected: February 2, 2016 - December 5, 2018

A class action has commenced on behalf of certain shareholders in Yangtze River Port and Logistics Limited. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Yangtze’s purported lease of the Wuhan Yangtze River Newport Logistics Center, the Company’s main asset, was a fabrication; (2) Yangtze’s only operating subsidiary, Wuhan Newport, was declared insolvent in China due to a number of default judgments against it; and (3) as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or  lacked a reasonable basis at all relevant times.

Shareholders may find more information at https://kseclaw.com/securities/yangtze-river-port-and-logistics-limited/?wire=3

Alkermes plc (NASDAQGS: ALKS)
Investors Affected: February 17, 2017 - November 1, 2018

A class action has commenced on behalf of certain shareholders in Alkermes plc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the FDA had advised Alkermes to follow a certain protocol in connection with its New Drug Application submission for its drug ALKS 5461; (2) Alkermes had failed to follow that protocol; (3) consequently, an FDA advisory committee voted 21 to 2 against the approval of ALKS 5461; and (4) as a result, Alkermes’ public statements were materially false and/or misleading at all relevant times.

Shareholders may find more information at https://kseclaw.com/securities/alkermes-plc/?wire=3

Maxar Technologies Inc. (NYSE: MAXR)
Investors Affected: March 29, 2018 - January 7, 2019

A class action has commenced on behalf of certain shareholders in Maxar Technologies Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Maxar improperly inflated the value of its intangible assets, among other accounting improprieties; (ii) Maxar’s highly-valued WorldView-4 was equipped with CMGs that were faulty and/or ill-suited for their designed and intended purpose; and (iii) as a result, Maxar’s public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://kseclaw.com/securities/maxar-technologies-inc/?wire=3

Tyme Technologies, Inc. (NASDAQCM: TYME)
Investors Affected: March 14, 2018 - January 18, 2019

A class action has commenced on behalf of certain shareholders in Tyme Technologies, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Tyme had not adequately designed the Phase II Study to present reliable results on the efficacy of SM-88 on pancreatic cancer; (ii) Tyme had failed to include an appropriate control group in its open-label Phase II clinical trial for SM-88; (iii) the omission of an appropriate control group distorted the reliability of data showing the efficacy of SM-88 in the Phase II Study; and (iv) as a result, Tyme’s public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://kseclaw.com/securities/tyme-technologies-inc/?wire=3

Kuznicki Law PLLC is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock.

CONTACT:
Kuznicki Law PLLC
Daniel Kuznicki, Esq.
445 Central Avenue, Suite 334
Cedarhurst, NY 11516
Email: dk@kclasslaw.com
Phone: (347) 696-1134
Cell: (347) 690-0692
Fax: (347) 348-0967